https://www.biospace.com/cocrystal-pharma-doses-first-subjects-in-clinical-study-of-cdi-988-for-pandemic-norovirus-and-coronavirus
Cocrystal Pharma, Inc., announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL...
clinical studycocrystalpharmadosesfirst
https://www.biospace.com/press-releases/cocrystal-pharma-reports-phase-1-results-with-oral-broad-acting-antiviral-drug-cdi-988-for-prophylaxis-and-treatment-of-norovirus-coronaviruses-and-other-viral-infections
cocrystalpharmareportsphaseresults
https://www.biospace.com/cocrystal-pharma-selects-lead-compound-for-further-development-against-coronaviruses
CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2
lead compoundcocrystalpharmaselectsdevelopment
https://scirp.org/journal/papercitationdetails?paperid=121963&JournalID=473
We studied cocrystal of bis(8-quinolinolato) copper(II) (CuQ2) and 7,7,8,8-tetracyanoquinodimethane (TCNQ), which change dramatically crystal shape in a moment...
morphologicalchangecocrystalbiscopper